blood cancer treatment

Stanford spent more than 20 years developing a blood-cancer transplant therapy; its first commercial patient has now been treated after a trial found 78% were free from moderate-to-severe GVHD at one year

Representative Image (AI-generated) A blood-cancer treatment that Stanford researchers have spent more than two decades developing…